Bivalirudin, a peptide anticoagulant, is a direct thrombin inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention.
Bivalirudin is a short, synthetic peptide. It is a potent and highly specific inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life.
Product Introduction
| Generic name |
Bivalirudin |
| Formula |
C98H138N24O33 |
| CAS No. |
128270-60-0 |
| Molecular Weight |
2180.29 |
| EINECS |
274-570-6 |
Chemical Properties
| Density |
1.52±0.1 g/cm3(Predicted) |
| Refractive Index |
1.675 |
| Storage Condition |
-20°C |
| Apperance |
White to off-white powder |
Application & Efficacy
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients under-going percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
Audited Supplier 
){kind=link}
){kind=link}